The Crystal Structures of Glycogen Synthase Kinase 3

Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development

Volumn , Issue , 2006, Pages 61-82

  Ter Haar, Ernst ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Crystal structures of GSK 3 inhibitor complexes; Primed phosphorylation mechanism; Wnt signaling pathway in developmental processes

Indexed keywords

EID: 84947315329     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470052171.ch4     Document Type: Chapter

References (71)

1. Woodgett J.R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J., 9, 2431-2438.
2. Eldar-Finkelman H. (2002). Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med., 8, 126-132.
3. Frame S., Cohen P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 359, 1-16.
4. Mukai F., Ishiguro K., Sano Y., Fujita S.C. (2002). Alternative splicing isoform of Tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem., 81, 1073-1083.
5. ter Haar E., Coll J.T., Austen D.A., Hsiao H.M., Swenson L., Jain J. (2001). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol., 8, 593-596.
6. Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C., Pearl L.H. (2001). Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate- primed substrate specificity and autoinhibition. Cell, 105, 721-732.
7. Johnson L.N., Noble M.E., Owen D.J. (1996). Active and inactive protein kinases: Structural basis for regulation. Cell, 85, 149-158.
8. Ruel L., Stambolic V., Ali A., Manoukian A.S., Woodgett J.R. (1999). Regulation of the protein kinase activity of Shaggy (Zeste-white3) by components of the Wingless pathway in Drosophila cells and embryos. J. Biol. Chem., 274, 21790-21796.
9. Ding V.W., Chen R.H., McCormick F. (2000). Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J. Biol. Chem., 275, 32475-32481.
10. Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., Dale T.C., Pearl L.H. (2003). Structural basis for recruitment of glycogen synthase kinase 3beta to the Axin-APC scaffold complex. EMBO J., 22, 494-501.
11. Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R., Pettman G., Mannix C., Culbert A.A., Brown M.J., Smith D.G., Reith A.D. (2001). The structure of phosphorylated GSK3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure (Camb.), 9, 1143-1152.
12. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. (2000). Regulation and localization of tyrosine 216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. USA, 97, 11074-11079.
13. Hartigan J.A., Xiong W.C., Johnson G.V. (2001). Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem. Biophys. Res. Commun., 284, 485-489.
14. Lesort M., Jope R.S., Johnson G.V. (1999). Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem., 72, 576-584.
15. Cole A., Frame S., Cohen P. (2004). Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J., 377, 249-255.
16. Lochhead P.A., Sibbet G., Morrice N., Cleghon V. (2005). Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell, 121, 925-936.
17. Jope R.S., Johnson G.V. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci, 29, 95-102.
18. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., Imahori K. (1993). Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett., 325, 167-172.
19. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., Singh T.J. (1997). Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell Biochem., 167, 99-105.
20. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., Anderton B.H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of Tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett., 147, 58-62.
21. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., Mandelkow E. (1992). Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett., 314, 315-321.
22. Cho J.H., Johnson G.V. (2003). Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites: Differential impact on microtubule binding. J. Biol. Chem., 278, 187-193.
23. Woodgett J.R., Cohen P. (1984). Multisite phosphorylation of glycogen synthase: Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim. Biophys. Acta., 788, 339-347.
24. Kuret J., Woodgett J.R., Cohen P. (1985). Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle: Identification of the sites phosphorylated by casein kinase-I. Eur. J. Biochem., 151, 39-48.
25. Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J. (1997). Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell, 90, 859-869.
26. Bellon S., Fitzgibbon M.J., Fox T., Hsiao H.M., Wilson K.P. (1999). The structure of phosphorylated p38gamma is monomeric and reveals a conserved activationloop conformation. Structure Fold Des., 7, 1057-1065.
27. Brown N.R., Noble M.E., Endicott J.A., Johnson L.N. (1999). The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell. Biol., 1, 438-443.
28. Cross D.A., Watt P.W., Shaw M., van der Kaay J., Downes C.P., Holder J.C., Cohen P. (1997). Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett., 406, 211-215.
29. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature, 378, 785-789.
30. Frame S., Cohen P., Biondi R.M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell, 7, 1321-1327.
31. Bertrand J.A., Thieffine S., Vulpetti A., Cristiani C., Valsasina B., Knapp S., Kalisz H.M., Flocco M. (2003). Structural characterization of the GSK3beta active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol., 333, 393-407.
32. Aoki M., Yokota T., Sugiura I., Sasaki C., Hasegawa T., Okumura C., Ishiguro K., Kohno T., Sugio S., Matsuzaki T. (2004). Structural insight into nucleotide recognition in Tau-protein kinase I/glycogen synthase kinase 3 beta. Acta Crystallogr. D Biol. Crystallogr., 60, 439-446.
33. Pierce A.C., Sandretto K.L., Bemis G.W. (2002). Kinase inhibitors and the case for CH.O hydrogen bonds in protein-ligand binding. Proteins, 49, 567-576.
34. Summers S.A., Kao A.W., Kohn A.D., Backus G.S., Roth R.A., Pessin J.E., Birnbaum M.J. (1999). The role of glycogen synthase kinase 3beta in insulinstimulated glucose metabolism. J. Biol. Chem., 274, 17934-17940.
35. Ross S.E., Erickson R.L., Hemati N., MacDougald O.A. (1999). Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. Mol. Cell. Biol., 19, 8433-8441.
36. Wagman A.S., Johnson K.W., Bussiere D.E. (2004). Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des., 10, 1105-1137.
37. Martinez A., Castro A., Dorronsoro I., Alonso M. (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev., 22, 373-384.
38. Schafer M., Goodenough S., Moosmann B., Behl C. (2004). Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res., 1005, 84-89.
39. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423, 435-439.
40. Hernandez F., Perez M., Lucas J.J., Mata A.M., Bhat R., Avila J. (2004). Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35: Implications for Alzheimer's disease. J. Biol. Chem., 279, 3801-3806.
41. Gould T.D., Zarate C.A., Manji H.K. (2004). Glycogen synthase kinase-3: A target for novel bipolar disorder treatments. J. Clin Psych., 65, 10-21.
42. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet., 36, 131-137.
43. Bhat R.V., Budd Haeberlein S.L., Avila J. (2004). Glycogen synthase kinase 3: A drug target for CNS therapies. J. Neurochem., 89, 1313-1317.
44. Meijer L., Skaltsounis A.L., Magiatis P., Polychronopoulos P., Knockaert M., Leost M., Ryan X.P., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchio A., Roe S.M., Pearl L., Greengard P. (2003). GSK-3- selective inhibitors derived from Tyrian purple indirubins. Chem. Biol., 10, 1255-1266.
45. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Díaz-Nido J., Avila J. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 278, 45937-45945.
46. ter Haar E., Walters W.P., Pazhanisamy S., Taslimi P., Pierce A.C., Bemis G.W., Salituro F.G., Harbeson S.L. (2004). Kinase chemogenomics: Targeting the human kinome for target validation and drug discovery. Mini Rev. Med. Chem., 4, 235-253.
47. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. (1997). Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960.
48. Hubbard S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J., 16, 5572-5581.
49. Dierick H., Bejsovec A. (1999). Cellular mechanisms of Wingless/Wnt signal transduction. Curr. Top. Dev. Biol., 43, 153-190.
50. Polakis P. (2000). Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
51. Wodarz A., Nusse R. (1998). Mechanisms of Wnt signaling in development. An. Rev. Cell. Dev. Biol., 14, 59-88.
52. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell, 108, 837-847.
53. Ikeda S., Kishida M., Matsuura Y., Usui H., Kikuchi A. (2000). GSK-3betadependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene, 19, 537-545.
54. Sperber B.R., Leight S., Goedert M., Lee V.M. (1995). Glycogen synthase kinase-3 beta phosphorylates Tau protein at multiple sites in intact cells. Neurosci. Lett., 197, 149-153.
55. Eklof Spink K., Fridman S.G., Weis W.I. (2001). Molecular mechanisms of betacatenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J., 20, 6203-6212.
56. Hart M.J., de los Santos R., Albert I.N., Rubinfeld B., Polakis P. (1998). Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr. Biol., 8, 573-581.
57. Behrens J., Jerchow B.A., Wurtele M., Grimm J., Asbrand C., Wirtz R., Kuhl M., Wedlich D., Birchmeier W. (1998). Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science, 280, 596-599.
58. Ikeda S., Kishida S., Yamamoto H., Murai H., Koyama S., Kikuchi A. (1998). Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J., 17, 1371-1384.
59. Weston C.R., Davis R.J. (2001). Signal transduction: Signaling specificity a complex affair. Science, 292, 2439-2440.
60. Cohen P., Frame S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell. Biol., 2, 769-776.
61. Jho E., Lomvardas S., Costantini F. (1999). A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. Biochem. Biophys. Res. Commun., 266, 28-35.
62. Willert K., Shibamoto S., Nusse R. (1999). Wnt-induced dephosphorylation of Axin releases beta-catenin from the Axin complex. Genes Dev., 13, 1768-1773.
63. Farr G.H. 3rd, Ferkey D.M., Yost C., Pierce S.B., Weaver C., Kimelman D. (2000). Interaction among GSK-3, GBP, axin, and APC in Xenopus axis specifi- cation. J. Cell. Biol., 148, 691-702.
64. Yost C., Farr G.H. 3rd, Pierce S.B., Ferkey D.M., Chen M.M., Kimelman D. (1998). GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell, 93, 1031-1041.
65. Yuan H., Mao J., Li L., Wu D. (1999). Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation. J. Biol. Chem., 274, 30419-30423.
66. Li L., Yuan H., Weaver C.D., Mao J., Farr G.H. 3rd, Sussman D.J., Jonkers J., Kimelman D., Wu D. (1999). Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J., 18, 4233-4240.
67. van Amerongen R., Nawijn M., Franca-Koh J., Zevenhoven J., van der Gulden H., Jonkers J., Berns A. (2005). Frat is dispensable for canonical Wnt signaling in mammals. Genes Dev., 19, 425-430.
68. van Amerongen R., Berns A. (2005). Re-evaluating the role of Frat in Wnt-signal transduction. Cell. Cycle, 4.
69. Culbert A.A., Brown M.J., Frame S., Hagen T., Cross D.A., Bax B., Reith A.D. (2001). GSK3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Taut dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett., 507, 288-294.
70. Hedgepeth C.M., Deardorff M.A., Rankin K., Klein P.S. (1999). Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by Axin. Mol. Cell. Biol., 19, 7147-7157.
71. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.